IMS Health buys trial-enrollment software startup

Health information heavyweight IMS Health has gobbled up DecisionView, a San Francisco-based provider of web-based software that analyzes patient enrollment in clinical trials via an acquisition. Venture-backed DecisionView--which has a customer roster that includes drug giants such as Merck ($MRK), GlaxoSmithKline ($GSK) and Roche ($RHHBY)--provides a tool for benchmarking enrollment trends by trial type and geography. Patient recruitment has been one of the biggest challenges to getting studies done on time, in an industry where every day a program is delayed can mean millions of dollars in lost opportunity. IMS, based in Danbury, CT, and DecisionView didn't reveal financial terms of the deal. Release | Article